Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$27.42 USD
-2.01 (-6.83%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $28.01 +0.59 (2.15%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.42 USD
-2.01 (-6.83%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $28.01 +0.59 (2.15%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Zacks News
Cassava Sciences, Inc. (SAVA) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $62.08 in the latest trading session, marking a -0.1% move from the prior day.
Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.
Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam
by Zacks Equity Research
Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.
Cassava Sciences, Inc. (SAVA) Stock Moves -0.52%: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $48.26 in the latest trading session, marking a -0.52% move from the prior day.
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $43.95, marking a +0.07% move from the previous day.
Do Options Traders Know Something About Cassava Sciences (SAVA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down
by Zacks Equity Research
Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.
Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.
Cassava (SAVA) Down as Quanterix Issues Statement on AD Study
by Zacks Equity Research
Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.
Cassava (SAVA) Responds to Charges Against its Integrity in AD Study
by Zacks Equity Research
Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.
Cassava (SAVA) Stock Up on Alzheimer's Candidate Update
by Zacks Equity Research
Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
Cassava Sciences (SAVA) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Cassava Sciences (SAVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $79.65 in the latest trading session, marking a +1.34% move from the prior day.
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?
by Aditi Saraogi
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $34.85, marking a -0.68% move from the previous day.
Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SAVA) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences
A Year Into the COVID-19 Pandemic: 5 Stock Winners
by Sweta Killa
Though the U.S. economy is far from pre-pandemic levels, it has shown solid improvement. Meanwhile, the stock market has strongly bounced back and reached new milestones.
Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why
by Zacks Equity Research
Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.